News

Not all herbal treatments were found to successfully treat moderate-to-severe eczema as previously thought.

A signaling mechanism can turn T-cells into destroyers.

Cornell scientists said they created a chemical tool that uses ultraviolet light to track inflammation and even control it. Their hope is it might work to treat inflammatory diseases, perhaps even multiple sclerosis.

A new drug for atopic dermatitis got FDA approval.

After a review of existing studies, the FDA today sent out a warning that surgery lasting three hours or more poses a threat of brain or other neurological damage in babies, fetuses, and toddlers.

The antibiotic oral vancomycin can potentially prevent C. difficile infections in patients undergoing stem cell transplants, new research finds.

Increasing the duration of sofosbuvir/ribavirin treatment can cure more patients with hepatitis C genotype 2 with cirrhosis.

In a letter, the Textile Rental Services Association strongly responded to the article. David F. Goldsmith, MSPH, PhD, wrote that the story on hospital laundry facilities could “misleadingly create false alarms.”

Responding to problems with long delays in getting care at Veterans Affairs facilities, the agency announced today it would expand the duties of some advanced practice nurses, but not of nurse-anesthetists. The American Medical Association was quick to respond.

A new article in the Journal of Allergy and Clinical Immunology argues that genetic studies of asthma, expected to be game-changers, have “delivered neither meaningful clinical diagnostic tools nor useful insights into disease pathogenesis.”

The American Academy of HIV Medicine in Washington, DC. has signed on as a "strategic partner" with MD Magazine and its sister publication Contagion.

Results of a 10-year study on bladder cancer risk with pioglitazone might be better than the five-year results led the US Food and Drug Administration to re-affirm that the danger is real--though slightly less than the preliminary data showed.

Extracorporeal shock therapy helped patients with diabetes improve their range of motion when suffering from "frozen shoulder" a study in Italy found.

The billion-dollar combination of pegpleranib and ranibizumab failed to meet primary endpoints in studies for the treatment of age-related macular degeneration.

Getting tested for HIV can be accompanied with the feeling of judgement. So if healthcare officials want to encourage testing, they might want to rely on peer-referral.

Autoimmune disease has been known to increase the risk of epilepsy, but it's new knowledge that a mother's rheumatoid arthritis impacts their offspring's epilepsy risk.

Previous research showed probiotics given to pregnant women during certain stages of pregnancy and post delivery reduced the likelihood of atopic dermatitis in their children. Recently published reports; however, may not agree.

Synjardy XR, a combination of empagliflozin and metformin hydrochloride, was approved this afternoon by the FDA for glucose management in type 2 diabetics. The drug is a collaboration between Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company.

Gilead Sciences is seeking approval of a single tablet, 12-week combination hepatitis C regimen for patients of all genotypes previously treated for the disease with direct-acting antivirals.

A research team has come up with a road map for physicians helping patients with multiple sclerosis feel less tired and lethargic. It's called the Berlin Treatment Algorithm.

Children with atopic dermatitis (AD) were reported to have a greater risk for developing contact dermatitis from some common ingredients of topical products than those with a history of contact dermatitis but no AD, in a recent comparison of patch testing responses in both groups.

Sitagliptin tablets proved more convenient and equally safe and effective as insulin injections in achieving glycemic control for people with diabetes admitted to hospitals for medical care or surgery, a five-center study found.

New methods are needed to study whether diet changes really help in multiple sclerosis.

Regeneron and Sanofi’s highly-anticipated atopic dermatitis drug dupilumab, trade name Dupixent, has been accepted by the European Medicines Agency (EMA) for review. The drug has performed well in trials and is considered an impending blockbuster.

Chronic idiopathic urticaria (CIU) typically lasts one to five years. Nevertheless, in 14% of CIU patients, the disease lasts longer than five years, and few predictors of its remission rate are available. However, a pair of Thai investigators recently showed that the results of two simple skin tests could predict two-year remission rates in patients with CIU.

Most patients with severe refractory juvenile ideiopathic arthritis-associated uveitis may get complete remission after six months of treatment with tocilizumab (Actemra/Roche.)

A study out of the University of Pittsburgh identifies significant comorbidity and negative outcomes in those with insomnia and asthma, and finds that even asthmatics who report no nighttime breathing disturbances still face a predisposition to sleeplessness.

Though all obese women are treated as though they are at high risk of getting diabetes during pregnancy, that's not true. Only a quarter of them do. A UK team has figured out how to assess risk.

Patients suffering from irritable bowel syndrome with constipation (IBS-C) may benefit from a new drug, plecanatide, making its way through the approval pipeline.

Why do many men decline to use the pre-exposure prophylaxis (PrEP) (Truvada) to reduce their high risk of the human immunodeficiency virus (HIV) infection? A new survey study out of the United Kingdom may have some of the answers.